SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-242801
Filing Date
2024-10-24
Accepted
2024-10-24 16:02:29
Documents
14
Period of Report
2024-10-22
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d846508d8k.htm   iXBRL 8-K 32248
2 EX-10.1 d846508dex101.htm EX-10.1 193596
  Complete submission text file 0001193125-24-242801.txt   386049

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rgls-20241022.xsd EX-101.SCH 2858
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgls-20241022_lab.xml EX-101.LAB 17996
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgls-20241022_pre.xml EX-101.PRE 11267
16 EXTRACTED XBRL INSTANCE DOCUMENT d846508d8k_htm.xml XML 3645
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35670 | Film No.: 241392600
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)